Fig. 2
From: Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer’s disease
Precision profiles of the CSF β-syn measurements using the three ELISAs. Performance in the proof-of-concept cohort (A-C) and the clinical cohort (D-F). In the figures, the levels of β-syn measured with each assay are plotted on the x-axis against the percentage coefficient of variation of the duplicate measurements (%CV) on the y-axis. The results were color-coded per group as follows: control, SCD-AD, MCI-AD, and AD-dem. For all the figures, the vertical dashed line represents the functional lowest limit of detection (LLoD) (i.e., mean of 16 blanks*10 × standard deviation of the blanks*assay’s CSF dilution factor). The horizontal line shows the limit of accepted precision (20% CV). CSF: cerebrospinal fluid, β-syn: beta-synuclein, SCD: subjective cognitive decline, AD: Alzheimer’s disease, MCI: mild cognitive impairment, AD-dem: dementia due to AD